Lucid Diagnostics LUCD Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Lucid Diagnostics in its filing.
Tagged under the XBRL concept us-gaap:Cash.
The official record: Lucid Diagnostics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Lucid Diagnostics's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Lucid Diagnostics's cash & equivalents?
- Lucid Diagnostics (LUCD) reported cash & equivalents of $27.88M in Q1 2026.
- How has Lucid Diagnostics's cash & equivalents changed year-over-year?
- Lucid Diagnostics's cash & equivalents increased by 10.6% year-over-year, from $25.2M to $27.88M.
- What is the long-term trend for Lucid Diagnostics's cash & equivalents?
- Over 5 years (2020 to 2025), Lucid Diagnostics's cash & equivalents has grown at a 215.5% compound annual growth rate (CAGR), from $111K to $34.71M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.